Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models

1 Sept 2009

Abstract excerpt

N-(2-aminophenyl)-4-[N-(pyridine-3yl-methoxy-carbonyl) aminomethyl] benzamide (MS-275) is a second generation histone deacetylase (HDAC) inhibitor with significant anti-tumor efficacy currently in clinical development. We investigated the effect of MS-275 treatment on various colon cancer cell lines, as well as on mouse xenograft models derived from human colorectal cancer. MS-275 exerted strong...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Signaling Pathways in Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19724929
DOI: 10.3892/ijo_00000406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer modelsPMID 19724929Read ↗

Immune modulation underpins the anti‐cancer activity of HDAC inhibitorsSemantic proximity Read ↗

Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future ConsiderationsSemantic proximity Read ↗

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in CancerSemantic proximity Read ↗

Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity.Semantic proximity Read ↗

Chemical perturbations impacting histone acetylation govern colorectal cancer differentiationSemantic proximity Read ↗

Histone acetylation and chemoresistance in colorectal cancer : an opportunity for effective personalized treatmentSemantic proximity Read ↗

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases <i>In vitro</i> and <i>In vivo</i>Semantic proximity Read ↗

Identifying Novel Actionable Targets in Colon CancerSemantic proximity Read ↗

Inhibition of histone deacetylases in melanoma—a perspective from bench to bedsideSemantic proximity Read ↗

Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agentsSemantic proximity Read ↗

NAA40 contributes to colorectal cancer growth by controlling PRMT5 expressionSemantic proximity Read ↗

Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colonSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.